Ultragenyx Pharmaceutical Inc Forecasted to Post FY2022 Earnings of $2.42 Per Share (RARE)

Share on StockTwits

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) – Equities researchers at Jefferies Financial Group upped their FY2022 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a research report issued on Tuesday, November 6th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biopharmaceutical company will earn $2.42 per share for the year, up from their prior estimate of $2.29.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Monday, November 5th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.94) by $0.20. Ultragenyx Pharmaceutical had a negative return on equity of 40.10% and a negative net margin of 508.70%. The company had revenue of $11.80 million for the quarter, compared to analyst estimates of $11.97 million. During the same quarter in the previous year, the firm earned ($1.87) earnings per share. The firm’s quarterly revenue was up 5800.0% compared to the same quarter last year.

A number of other brokerages have also weighed in on RARE. SunTrust Banks boosted their price target on Ultragenyx Pharmaceutical to $83.00 and gave the stock a “positive” rating in a research note on Monday, August 20th. Bank of America boosted their price target on Ultragenyx Pharmaceutical from $72.00 to $94.00 and gave the stock a “buy” rating in a research note on Tuesday, September 11th. Barclays restated an “overweight” rating and set a $92.00 price target (up previously from $74.00) on shares of Ultragenyx Pharmaceutical in a research note on Friday, August 3rd. Morgan Stanley set a $70.00 price target on Ultragenyx Pharmaceutical and gave the stock a “hold” rating in a research note on Monday, October 29th. Finally, Piper Jaffray Companies dropped their price target on Ultragenyx Pharmaceutical to $70.00 and set an “overweight” rating on the stock in a research note on Friday, October 26th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $75.95.

RARE opened at $52.24 on Thursday. Ultragenyx Pharmaceutical has a 1 year low of $41.67 and a 1 year high of $90.98. The stock has a market capitalization of $2.71 billion, a price-to-earnings ratio of -6.97 and a beta of 2.34.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Xact Kapitalforvaltning AB boosted its position in Ultragenyx Pharmaceutical by 10.6% in the second quarter. Xact Kapitalforvaltning AB now owns 7,323 shares of the biopharmaceutical company’s stock valued at $563,000 after buying an additional 700 shares during the last quarter. GAM Holding AG lifted its holdings in Ultragenyx Pharmaceutical by 2.0% in the second quarter. GAM Holding AG now owns 50,700 shares of the biopharmaceutical company’s stock valued at $3,897,000 after acquiring an additional 1,000 shares during the period. Metropolitan Life Insurance Co. NY lifted its holdings in Ultragenyx Pharmaceutical by 7.3% in the second quarter. Metropolitan Life Insurance Co. NY now owns 15,187 shares of the biopharmaceutical company’s stock valued at $1,167,000 after acquiring an additional 1,037 shares during the period. State Board of Administration of Florida Retirement System lifted its holdings in Ultragenyx Pharmaceutical by 4.4% in the second quarter. State Board of Administration of Florida Retirement System now owns 26,319 shares of the biopharmaceutical company’s stock valued at $2,023,000 after acquiring an additional 1,100 shares during the period. Finally, Wells Fargo & Company MN lifted its holdings in Ultragenyx Pharmaceutical by 5.0% in the first quarter. Wells Fargo & Company MN now owns 24,200 shares of the biopharmaceutical company’s stock valued at $1,234,000 after acquiring an additional 1,149 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

In related news, EVP Karah Herdman Parschauer sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $78.53, for a total value of $392,650.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Shalini Sharp sold 6,700 shares of the company’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $90.07, for a total value of $603,469.00. Following the completion of the sale, the chief financial officer now owns 56,828 shares in the company, valued at approximately $5,118,497.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 37,250 shares of company stock worth $2,747,319. 8.40% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Read More: Outstanding Shares, Buying and Selling Stocks

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply